LIVING LONGER WITH GLIOBLASTOMA IS POSSIBLE
Care Oncology’s patented COC Protocol™ has proven to increase the survival in Glioblastoma patients when used in combination with standard-of-care*.
A clinical trial performed in the U.K., comprised of a 95-patient cohort, resulted in a median overall survival of 27 months when the COC Protocol was used in addition to standard-of-care. Compared to median overall survival of 15.6 months¹ and 14.8 months² with standard-of-care alone.
See long term Glioblastoma survivors in the news who use the COC Protocol:
Patient 1 now 4 years out post diagnosis – Featured in The Telegraph
Patient 2 now 3 years out post diagnosis – Featured in Daily Mail
WHAT IS THE COC PROTOCOL?
The COC Protocol is an adjunctive cancer therapy comprised of a combination of well-established, FDA-approved medications. The medications are widely prescribed, with outstanding safety profiles. Research has demonstrated significant “off-target”, anti-cancer activity of the medications individually. For example, one medication in the protocol is a drug often prescribed for people with type 2 diabetes called Metformin. Many studies have demonstrated the anti-cancer activity of metformin across most types of cancer. A few example of this research include the following studies:
Researchers at MD Andersen found that among 2,529 women with early-stage breast cancer, the pathological complete response rate after chemotherapy was higher (24%) in diabetic patients who had received metformin than in diabetic patients who had not received metformin (8%) and in nondiabetic patients (16%). In the second study, a group in the Department of Gastrointestinal Medical Oncology found that among 255 diabetic patients, the risk of developing pancreatic cancer was 62% lower in those who received metformin than in those who did not.
A study at the University of Pennsylvania reported dramatic improvement in local recurrence in 16 lung cancer patients who received chemoradiation while taking metformin.
This study followed 87,344 men diagnosed with prostate cancer between 2000 and 2008. The median overall survival for non-diabetics (not taking metformin), diabetics on metformin, and diabetics not on metformin was 7.1, 9.1, and 7.4 years, respectively. The study concluded that both overall survival and cancer-specific survival were significantly prolonged among the diabetics on metformin.
View COC Treatment Process now by filling out the following form:
WHY AREN’T THESE MEDICATIONS ALREADY BEING USED?
Mostly due to financial reasons. The medications comprising the COC Protocol are “off-patent”, therefore, pharmaceutical companies are unable to re-coup the cost necessary to win approval for a new indication. Putting these well-researched medications to use for cancer immediately presents much needed therapies to cancer patients with minimal side-effects. The COC protocol was conceived to finally realize the potential of these medicines in a thoughtful, responsible, and ethical manner. Starting in London in 2013, The COC Protocol has been safely administered to over 1400 patients by trained providers through a carefully monitored program.
WHAT ARE THE ADVANTAGES TO USING EXISTING MEDICATIONS?
The use of existing medications has several advantages, the most important being safety: Decades of clinical experience have documented the safety-profile, side-effects, and drug-drug interactions of the individual medications in the COC Protocol.
WHY USE A COMBINATION OF MEDICATIONS?
It is well-accepted that complex diseases like cancer respond better to combination therapies. The medications in the COC Protocol synergistically target cancer cells through a multitude of well-established mechanisms. In general, cancer cell’s pathological multiplication is the result of two processes: First, a breakdown of the normal signaling pathways that regulate cellular division. And second, unregulated energy metabolism that fuels the uncontrolled growth of cancer cells. The COC Protocol uniquely targets both processes. By starving cancer cells of energy substrates, the COC Protocol reduces the capacity of cancer cells to defend themselves against chemotherapy and radiation. The COC protocol also acts on the many dysregulated signaling pathways within cancer cells helping to enable a process called apoptosis, or “programmed cell death,” allowing chemotherapy and radiation to kill cancer cells more effectively. Finally, medications in the COC Protocol have been shown to operate by stimulating the immune system to fight your cancer by activating an important class of immune cells called Tumor Infiltrating Lymphocytes.
WHAT TYPES OF CANCER DOES THE COC PROTOCOL TREAT?
Unlike targeted therapies, the COC Protocol is not limited by the presence of a specific genetic lesion. Importantly, because the medications in the COC Protocol target the ubiquitous metabolic and signaling dysfunction that occurs within cancer cells, regardless of the tissue of origin, the COC treatment is not limited to a specific type of cancer. The research has clearly shown that the medications in the COC Protocol have anti-cancer activity across the majority of cancer types.
1 Stupp R, Hegi ME, Idbaih A, et al. Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multicenter, phase III trial. In: Program and abstracts of the 2017 Annual Meeting of the American Association for
2 Cancer Research; April 1-5, 2017; Washington, DC. Abstract LBA AACR CT007.
Public Health England survival data for patients under 70, diagnosed with GBM, between 2007 and 2010.